TLD1433 Photosensitizer Inhibits Conjunctival Melanoma Cells in Zebrafish Ectopic and Orthotopic Tumour Models

The ruthenium-based photosensitizer (PS) TLD1433 has completed a phase I clinical trial for photodynamic therapy (PDT) treatment of bladder cancer. Here, we investigated a possible repurposing of this drug for treatment of conjunctival melanoma (CM). CM is a rare but often deadly ocular cancer. The...

Full description

Bibliographic Details
Main Authors: Quanchi Chen, Vadde Ramu, Yasmin Aydar, Arwin Groenewoud, Xue-Quan Zhou, Martine J. Jager, Houston Cole, Colin G. Cameron, Sherri A. McFarland, Sylvestre Bonnet, B. Ewa Snaar-Jagalska
Format: Article
Language:English
Published: MDPI AG 2020-03-01
Series:Cancers
Subjects:
Online Access:https://www.mdpi.com/2072-6694/12/3/587

Similar Items